The Virology Core will be responsible for the generating full-length viral genome sequences from the majority of study subjects in this U19 through a highly organized, and high-throughput 454 sequencing approach. As these data can be generated rapidly, these data will also serve to identify subjects and epitopes for downstream analysis for the proposed specific studies on outlined in Projects 1-4. To rule out any confounding effects on our study design of possible virus-specific interferon resistance associated with prior interferon therapy failure, the Virology Core will also determine whether there is any evidence of genotypic resistance to interferon in subjects previously having failed interferon therapy. Specifically, the Virology Core will:
Aim 1 : Characterize full genome viral sequences from all HCV+ study subjects to identify epitope-specific sequence data for downstream phenotype and functional assays.
Aim 2 : Determine whether subjects who failed to achieve prior sustained virologic response (SVR) under interferon and ribavirin therapy exhibit any IFN genotypic resistance markers

Public Health Relevance

Knowledge of each subject's viral sequence will be important to ensure that the proper reagents (peptides, tetramers) are used for each assay, and to enable where needed autologous peptide screening to known T cell epitopes, but even more importantly to also ensure that viral escape has not altered the immune response or phenotype of responding cells to be included in analyses. It will also be important to demonstrate that prior interferon treatment failure is not due to development of interferon resistance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI082630-06
Application #
8726068
Study Section
Special Emphasis Panel (ZAI1-LAR-I (J1))
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
6
Fiscal Year
2014
Total Cost
$84,859
Indirect Cost
$23,625
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Lin, Wenyu; Zhu, Chuanlong; Hong, Jian et al. (2015) The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. J Hepatol 62:1024-32
Jilg, Nikolaus; Lin, Wenyu; Hong, Jian et al. (2014) Kinetic differences in the induction of interferon stimulated genes by interferon-* and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59:1250-61
Kroy, Daniela C; Ciuffreda, Donatella; Cooperrider, Jennifer H et al. (2014) Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146:550-61
Lee, Mark N; Ye, Chun; Villani, Alexandra-ChloƩ et al. (2014) Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 343:1246980
Crawford, Alison; Angelosanto, Jill M; Kao, Charlly et al. (2014) Molecular and transcriptional basis of CD4? T cell dysfunction during chronic infection. Immunity 40:289-302
Feeney, Eoin R; Chung, Raymond T (2014) Antiviral treatment of hepatitis C. BMJ 348:g3308
Fackler, Oliver T; Murooka, Thomas T; Imle, Andrea et al. (2014) Adding new dimensions: towards an integrative understanding of HIV-1 spread. Nat Rev Microbiol 12:563-74
Xiao, Yanping; Yu, Sanhong; Zhu, Baogong et al. (2014) RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 211:943-59
Veerapu, Naga Suresh; Park, Su-Hyung; Tully, Damien C et al. (2014) Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 124:3469-78
Ussher, James E; Bilton, Matthew; Attwod, Emma et al. (2014) CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol 44:195-203

Showing the most recent 10 out of 72 publications